CVS Health CVS, the pharmacy retail and PBM powerhouse, has witnessed a substantial 24% decline over the past three months. In fact, during the last trading session, the stock closed at $56.62, which marked a more than 47% plunge from its 52-week high of $83.25 and was quite close to its 52-week low of $52.77. Not only this, the stock is currently trading below its 50-day and 200-day moving averages, indicating the possibility of a further bearish shift in the stock's price. CVS Below 50 & 200 Day SMA Zacks Investment Research Image Source: Zacks Investment Research As the stock struggles to keep pace, it is now a big question for investors whether to get rid of CVS Health or grab a few more shares because the stock is hovering around its rock bottom. While the stock has been grappling with the industry-wide phenomenon of pharmacy reimbursement pressure, a turnaround might be in the cards, given its strategic initiatives that can change investors' perspectives in favor of CVS Health. Let us delve deeper. What Pulled CVS Down? Pharmacy Reimbursement Crisis: The entire retail pharmacy industry is currently grappling with continued pressure from non-reimbursable pharmacy expenses, which are significantly pulling down mass demand for prescription as well as over-the-counter drugs and vaccinations. Going by a National Association of Chain Drugs report, payors are substantially shrinking reimbursement, many times below the cost of buying and dispensing prescription drugs. This is putting substantial and unsustainable financial pressure on the companies to the extent that many of the industry players over the past year were seen either shutting down their entire business, reducing the number of stores or going private. CVS Health, like its industry peers, is severely affected by this ongoing crisis. In fact, despite the company reporting revenue expansion, the shrinking margins and earnings are pretty alarming. Labor Shortage Plagues the System: Despite the end of the healthcare emergency, the lingering effects forced frontline pharmacy retail workers like doctors and medical staff to leave the field. According to the article "A Public Health Crisis: Staffing Shortages in Health Care," published in Favorite Healthcare Staffing, the WHO predicts a shortfall of 15 million healthcare workers worldwide in 2030. This is naturally creating huge operational hazards for companies like CVS Health, resulting in productivity loss. Going by a 2024 Boston Globe report, CVS has, in fact, acknowledged an “unprecedented” labor shortage among pharmacists and other staff, leading customers to complain about longer lines, unanswered phones and unclean stores. Visible Silver Lining for CVS 2025 Roadmap Looks Impressive CVS Health is committed to improving its Medicare Advantage margins in 2025. Given its predicted baseline performance, 2025 will be the first stage in a three to four-year journey to re-establish the company's target margins of 4 to 5%. Improved Star Ratings in 2025 might generate a $700 million tailwind, depending on membership retention levels. The remainder of the company's margin gain in 2025 will be driven by pricing initiatives in an environment where it is experiencing headwinds from an insufficient rate notice and prescription medication coverage changes that significantly raise plan liability. CVS Health is accelerating long-term enterprise productivity measures to streamline and enhance its processes. The company's target remains to achieve low double-digit adjusted EPS growth in 2025. Shares Outperform Industry Over the past month, shares of CVS Health have lost 6.1%. However, the stock has outperformed the industry’s 9.6% decline. While one of the company’s peers, Herbalife Ltd HLF, registered a 2% decline, outperforming CVS, the company’s prime competitor and another colossal pharmacy retail player, Walgreens Boots WBA, suffered a sharper decline of 29.4% during this period due to disappointing quarterly results and further guidance cut due to unfavorable industry forecasts. One-Month Price Comparison Zacks Investment Research Image Source: Zacks Investment Research Upbeat Estimates With CVS’ second-quarter 2024 results approaching, we expect the company to fare better than WBA. Not to forget, the company has the power to minimize its pharmacy reimbursement-related issues by adjusting its in-house PBM business strategies. The Zacks Consensus Estimate points to revenue improvements of 3.1% and 5.5% for 2024 and 2025, respectively. However, reimbursement issues are likely to continue through the rest of 2024, creating significant bottom-line pressure for CVS Health. The Zacks Consensus Estimate indicates an earnings decline of 19.7% in 2024. However, there is some hope for investors that 2025 might get brighter, with the estimates showing a 10.6% improvement in earnings from the year-ago period. The stock currently has a Growth Score of A. Zacks Investment Research Image Source: Zacks Investment Research Waiting for a Better Entry Point Seems Prudent As we have already discussed, the stock is currently positioned below its moving averages, which indicates potential negative movement. Further, the current earnings estimates show no visible sign of improvement until 2025. In terms of valuation too, CVS Health’s forward 12-month price-to-earnings (P/E) is 7.65X, a premium to the market's average of 7.09X. The company is also trading at a significant premium to other industry players like Walgreens Boots (4.9X) and Herbalife (6.8X). This suggests that investors may be paying a higher price relative to the company's expected earnings growth. Premium Valuation Zacks Investment Research Image Source: Zacks Investment Research Accordingly, despite the recent dip in share prices, this might not be the ideal time to invest in CVS Health. However, those who already own this Zacks Rank #3 (Hold) stock may stay invested as the company's financial stability and 2025 roadmap offer potential pathways to recovery. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CVS Health Corporation (CVS):Free Stock Analysis Report Herbalife Ltd (HLF):Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
CVS Health (CVS) Falls 24% in 3 Months: Should You Buy the Dip?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...